Krystal Biotech, Inc. $KRYS Stock Sold by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC lowered its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 44.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 10,525 shares of the company’s stock after selling 8,525 shares during the quarter. Lisanti Capital Growth LLC’s holdings in Krystal Biotech were worth $3,500,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Heritage Family Offices LLP purchased a new stake in shares of Krystal Biotech in the third quarter worth approximately $25,000. Silvant Capital Management LLC purchased a new stake in shares of Krystal Biotech during the 2nd quarter worth $30,000. Integrated Wealth Concepts LLC purchased a new position in Krystal Biotech in the second quarter valued at about $46,000. Western Wealth Management LLC bought a new position in Krystal Biotech in the first quarter worth about $34,000. Finally, Signaturefd LLC raised its holdings in Krystal Biotech by 27.3% in the third quarter. Signaturefd LLC now owns 168 shares of the company’s stock worth $56,000 after purchasing an additional 36 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have commented on the stock. Royal Bank Of Canada decreased their price target on shares of Krystal Biotech from $400.00 to $375.00 and set an “outperform” rating for the company in a research report on Tuesday, November 3rd. Weiss Ratings downgraded shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, November 4th. HC Wainwright reiterated a “buy” rating and set a $361.00 price objective on shares of Krystal Biotech in a report on Thursday, October 15th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Wednesday, September 23rd. Finally, Citigroup reduced their price objective on Krystal Biotech from $416.00 to $412.00 and set a “buy” rating for the company in a research note on Tuesday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $375.00.

Krystal Biotech Stock Up 0.8%

Shares of KRYS opened at $308.81 on Thursday. The company has a market capitalization of $9.15 billion, a price-to-earnings ratio of 41.59 and a beta of 0.56. Krystal Biotech, Inc. has a 52 week low of $198.02 and a 52 week high of $382.54. The stock’s 50-day moving average price is $329.35 and its 200-day moving average price is $309.43.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.26. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. The company had revenue of $127.34 million during the quarter, compared to analysts’ expectations of $125.77 million. As a group, equities analysts anticipate that Krystal Biotech, Inc. will post 7.74 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company’s stock, valued at $16,456,000. The trade was a 33.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the transaction, the insider owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. This represents a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.